Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy



Status:Completed
Conditions:Endocrine
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:10/19/2018
Start Date:March 10, 2010
End Date:December 21, 2012

Use our guide to learn which trials are right for you!

A Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Cinacalcet for the Treatment of Hypercalcemia in Subjects With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy

This study is designed to demonstrate the efficacy and to assess the safety of cinacalcet for
the reduction of hypercalcemia in patients with primary hyperparathyroidism for whom
parathyroidectomy is indicated on the basis of an elevated corrected total serum calcium, but
who are unable to undergo parathyroidectomy.

The study will consist of a 30-day screening phase, a 12-week placebo-controlled
dose-titration phase, and a 16-week placebo-controlled efficacy assessment phase (EAP).
Participants who complete 28 weeks on study will continue into an open-label safety extension
phase for 24 weeks of investigational cinacalcet treatment.

Inclusion Criteria:

- age ≥ 18 years

- diagnosis of primary hyperparathyroidism (HPT)

- subjects must have the following laboratory values:

1. local/historical laboratory result showing a corrected total serum calcium > 1
mg/dL (0.25 mmol/L) above the upper limit of normal and

≤ 12.5 mg/dL (3.12 mmol/L) within the past 12 months, and

- local/historical laboratory result showing a plasma parathyroid horone (PTH)
> 75% of upper limit of normal within the past 12 months, and

- one central laboratory draw at the screen visit showing a corrected total
serum calcium > 11.3 mg/dL (2.82 mmol/L) and ≤ 12.5 mg/dL (3.12 mmol/L), and

- one central laboratory draw at the screen visit showing a plasma PTH > 55
pg/mL (5.8 pmol/L) OR

2. two central laboratory draws performed during the screening period at least 7
days apart, showing a

- corrected total serum calcium > 11.3 mg/dL (2.82 mmol/L) and ≤ 12.5 mg/dL
(3.12 mmol/L), and

- plasma PTH > 55 pg/mL (5.8 pmol/L)

- not able to undergo parathyroidectomy for ≥ 1 of the following reasons:

- failed parathyroidectomy

- comorbid conditions contraindicating parathyroidectomy

- parathyroidectomy not considered appropriate or is not feasible by primary
physician and subject

- before any study-specific procedure is performed, the appropriate written informed
consent must be obtained

Exclusion Criteria:

- symptoms attributable to hypercalcemia, requiring immediate medical intervention, as
judged by the investigator (including acute kidney stone, nausea and vomiting
requiring intravenous hydration, confusion, lethargy, stupor, or coma)

- unstable medical condition, defined as having been hospitalized within 30 days before
the date of informed consent, or otherwise unstable in the judgment of the
investigator

- administration of drugs that increase serum calcium concentration, including but not
limited to thiazide diuretics or lithium

- initiated bisphosphonate therapy or changed bisphosphonate dose within 12 weeks before
the date of informed consent

- current administration of drugs for ventricular arrhythmia

- unable to provide informed consent, or is at risk for poor compliance with study
procedures

- currently enrolled in another investigational device or drug study(s), or completed
such study within 30 days before the date of informed consent

- known hypersensitivity to or unable to tolerate cinacalcet

- received treatment with cinacalcet within 60 days before the date of informed consent

- history of seizures or an adjustment of anti-seizure medication within 12 weeks before
the date of informed consent

- family history or diagnosis a genetic syndrome, such as familial benign hypocalciuric
hypercalcemia (FBHH) or multiple endocrine neoplasia type 1 (MEN1) and type 2 (MEN2),
where primary HPT is one of the clinical manifestations of familial benign
hypocalciuric hypercalcemia (FBHH)

- refused to use highly effective contraceptive measures (as determined by the
investigator) throughout the study

- pregnant or breastfeeding
We found this trial at
23
sites
?
mi
from
San Diego, CA
Click here to add this to my saved trials
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Aventura, FL
Click here to add this to my saved trials
?
mi
from
Clearwater, FL
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
?
mi
from
Detroit, MI
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
?
mi
from
Kenner, LA
Click here to add this to my saved trials
?
mi
from
Lake Forest, CA
Click here to add this to my saved trials
?
mi
from
Lancaster, CA
Click here to add this to my saved trials
?
mi
from
Los Gatos, CA
Click here to add this to my saved trials
?
mi
from
Miami, FL
Click here to add this to my saved trials
Mission Viejo, California 92691
?
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
Morehead City, North Carolina 28557
?
mi
from
Morehead City, NC
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Orange, CA
Click here to add this to my saved trials
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
?
mi
from
Randwick,
Click here to add this to my saved trials
?
mi
from
Washington,
Click here to add this to my saved trials
?
mi
from
Weston, FL
Click here to add this to my saved trials